Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,056 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Thrombosis Clear all
Completed No phase listed Observational

Platelet Sub-study of the TWILIGHT Trial

NCT04001374
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Ticagrelor, ASA
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 7, 2026, 1:14 AM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Heparin and the Reduction of Thrombosis (HART) Trial

NCT00779558
View directory record Official record
Conditions
Thrombosis
Interventions
Heparin sulfate infusion at 10 units/kg/hour, Placebo infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
View directory record Official record
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Completed No phase listed Observational

Anatomic Outcomes Following Ozurdex Injections

NCT01282411
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Not listed
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Breath Analysis Technique to Diagnose Pulmonary Embolism

NCT00368836
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
BreathScreen PE
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 7, 2026, 1:14 AM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 7, 2026, 1:14 AM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 7, 2026, 1:14 AM EDT
Not listed No phase listed Observational

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer

NCT02507180
View directory record Official record
Conditions
Pregnancy, Deep Vein Thrombosis
Interventions
LEFt clinical decision rule
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
16 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 7, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers

NCT07159269
View directory record Official record
Conditions
Cardiovascular Disease Acute, Emergency Department Patient, Heart Failure Acute, Pulmonary Embolism (Diagnosis), Point of Care Ultrasound (POCUS), Cardiac Tamponade, Pericardial Effusion, Diagnostic Imaging, Medical Training, Implementation Science
Interventions
Cardiac point-of-care ultrasound (POCUS) training and clinical pathway
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 7, 2026, 1:14 AM EDT
Withdrawn No phase listed Observational

Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux

NCT00378027
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 7, 2026, 1:14 AM EDT
Active, not recruiting Not applicable Interventional

Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

NCT03250247
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Interventions
Stents
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
29
States / cities
Orange, California • San Francisco, California • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

NCT04574895
View directory record Official record
Conditions
Venous Thromboembolism, Pediatrics, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Hematology Review
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 21 Years
Enrollment
17,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 7, 2026, 1:14 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Terminated Not applicable Interventional Results available

SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines

NCT01670188
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Pneumatic SCD - VenaFlow System (DJO Global)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 7, 2026, 1:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients

NCT01325779
View directory record Official record
Conditions
Lower Extremity Deep Venous Thrombosis
Interventions
heparin, enoxaparin
Drug
Lead sponsor
Lisa Louwers
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 7, 2026, 1:14 AM EDT
Completed No phase listed Observational

Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery

NCT03931031
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 7, 2026, 1:14 AM EDT